Overview

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Hypothesis: the intracellular concentrations of raltegravir (RAL) and etravirine (ETV) administrated as 800 and 400 mg once a day, respectively, are similar to those obtained with the standard doses of 400 and 200 mg/12h, respectively. Objective: To analyze the plasma and intracellular concentrations of RAL and ETV administrated as 800 and 400 mg once daily respectively compared with standard doses of 400 and 200 mg/12h, respectively, and if they support its once daily administration.
Phase:
Phase 4
Details
Lead Sponsor:
Hospitales Universitarios Virgen del RocĂ­o
Treatments:
Etravirine
Raltegravir Potassium